New biomarkers have been identified that help in predicting the risk of death in Ebola patients.
reveals a new study.
The results come from scientists at the Department of Energy's Pacific Northwest National Laboratory and their colleagues at the University of Wisconsin-Madison, Icahn School of Medicine at Mount Sinai, the University of Tokyo and the University of Sierra Leone. The results were published online in the journal Cell Host & Microbe.
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.
Advertisement
‘About 11 biomarkers discovered can help distinguish fatal infections and non-fatal infections; and can also predict the risk of death in Ebola patients.’
Tweet it Now
The findings could allow clinicians to prioritize the scarce treatment resources available and provide them to the sickest patients, said the senior author of the study, Yoshihiro Kawaoka, a virology professor at the UW-Madison School of Veterinary Medicine.
The focus of the study were blood samples from Ebola patients that were obtained during the outbreak in Sierra Leone in 2014. The Wisconsin team obtained 29 blood samples from 11 patients who ultimately survived and nine blood samples from nine patients who died from the virus.
![New 'Finger-Prick Test' Diagnoses Ebola Virus Disease Within Minutes]( "New 'Finger-Prick Test' Diagnoses Ebola Virus Disease Within Minutes")
A point-of-care Ebola Virus Disease test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional method.
The Wisconsin team inactivated the virus according to approved protocols, developed in part at PNNL, and then shipped the samples to PNNL and other institutions for analysis.
The team looked at activity levels of genes and proteins as well as the amounts of lipids and byproducts of metabolism.
The team found 11 biomarkers that distinguish fatal infections from non-fatal ones and two that, when screened for early upon symptom onset, accurately predict which patients are likely to die.
"Our team studied thousands of molecular clues in each of these samples, sifting through extensive data on the activity of genes, proteins, and other molecules to identify those of most interest," said Katrina Waters, the leader of the PNNL team and a corresponding author of the paper.
"This may be the most thorough analysis yet of blood samples of patients infected with the Ebola virus."
The team found that survivors had higher levels of some immune-related molecules and lower levels of others compared to those who died. Plasma cytokines, which are involved in immunity and stress response, were higher in the blood of people who perished.
Fatal cases had unique metabolic responses compared to survivors, higher levels of virus, changes to plasma lipids involved in processes like blood coagulation, and more pronounced activation of some types of immune cells.
Pancreatic enzymes also leaked into the blood of patients who died, suggesting that damage from these enzymes contributes to the tissue damage characteristic of fatal Ebola virus disease.
The scientists found that levels of two biomarkers, known as L-threonine (an amino acid) and vitamin-D-binding-protein, may accurately predict which patients live and which die. Both were present at lower levels at the time of admission in the patients who ultimately perished.
The team found that many of the molecular signals present in the blood of sick, infected patients overlap with sepsis, a condition in which the body in response to infection by bacteria or other pathogens - mounts a damaging inflammatory reaction.
Fifteen PNNL scientists contributed to the study. Among the corresponding authors of the study are three PNNL scientists: Waters, Thomas Metz and Richard D. Smith. Three additional PNNL scientists Jason P. Wendler, Jennifer E. Kyle and Kristin E. Burnum-Johnson are among six scientists who share "first author" honors.
Source: Eurekalert
New 'Finger-Prick Test' Diagnoses Ebola Virus Disease Within Minutes
A point-of-care Ebola Virus Disease test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional method.
Advertisement
The Wisconsin team inactivated the virus according to approved protocols, developed in part at PNNL, and then shipped the samples to PNNL and other institutions for analysis.
The team looked at activity levels of genes and proteins as well as the amounts of lipids and byproducts of metabolism.
The team found 11 biomarkers that distinguish fatal infections from non-fatal ones and two that, when screened for early upon symptom onset, accurately predict which patients are likely to die.
"Our team studied thousands of molecular clues in each of these samples, sifting through extensive data on the activity of genes, proteins, and other molecules to identify those of most interest," said Katrina Waters, the leader of the PNNL team and a corresponding author of the paper.
"This may be the most thorough analysis yet of blood samples of patients infected with the Ebola virus."
The team found that survivors had higher levels of some immune-related molecules and lower levels of others compared to those who died. Plasma cytokines, which are involved in immunity and stress response, were higher in the blood of people who perished.
Fatal cases had unique metabolic responses compared to survivors, higher levels of virus, changes to plasma lipids involved in processes like blood coagulation, and more pronounced activation of some types of immune cells.
Pancreatic enzymes also leaked into the blood of patients who died, suggesting that damage from these enzymes contributes to the tissue damage characteristic of fatal Ebola virus disease.
The scientists found that levels of two biomarkers, known as L-threonine (an amino acid) and vitamin-D-binding-protein, may accurately predict which patients live and which die. Both were present at lower levels at the time of admission in the patients who ultimately perished.
The team found that many of the molecular signals present in the blood of sick, infected patients overlap with sepsis, a condition in which the body in response to infection by bacteria or other pathogens - mounts a damaging inflammatory reaction.
Fifteen PNNL scientists contributed to the study. Among the corresponding authors of the study are three PNNL scientists: Waters, Thomas Metz and Richard D. Smith. Three additional PNNL scientists Jason P. Wendler, Jennifer E. Kyle and Kristin E. Burnum-Johnson are among six scientists who share "first author" honors.
Source: Eurekalert
New Genomics Lab in Liberia Monitors Genetic Changes in the Deadly Ebola Virus
Evaluating changes in the deadly Ebola virus in real time was essential to determine whether those changes could have an impact on diagnostics and therapeutics or not.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
The AI method shows promise in identifying imaging biomarkers for diagnosing ADHD.
Diagnosed autistic individuals showed increased premature mortality in the UK, highlighting urgent needs to address associated inequalities.
Study reveals a correlation between hearing impairment and distinct brain region variances, contributing to dementia.
Financial impact of caring for individuals with neurodegenerative disorders reaches hundreds of billions annually in the United States.
Experts emphasize that addressing the skills gap demands immediate attention and innovative solutions, including education, re-training, and significant time investment.